Huons said Nov. 17 that its research was selected as a late-breaking abstract for the annual meeting of The Obesity Society, held Nov. 14-17 in National Harbor, Maryland.
|
MC4R is a receptor in the hypothalamus that plays a role in regulating appetite and energy balance. Activating the receptor can promote satiety and influence energy metabolism.
Existing approved MC4R-targeting treatments for certain rare forms of obesity are injectable peptide drugs. Huons is developing HUC1-622 as a potential oral alternative.
According to the company, HUC1-622 maintained its activity in the presence of agouti-related peptide(AgRP), a naturally occurring protein that stimulates appetite by inhibiting MC4R signaling.
Preclinical experiments also showed that receptor signaling persisted after treatment was discontinued, suggesting the compound may have prolonged activity. Repeated oral administration reduced body weight and fat in obese animal models.
The company also reported that HUC1-622 demonstrated greater selectivity for MC4R than for MC1R, another melanocortin receptor involved in skin pigmentation.
Activation of MC1R by existing peptide-based MC4R agonists can cause increased skin pigmentation. The company said its findings suggest that HUC1-622 may have a lower risk of such effects, although this has not been established in humans.
The results remain preclinical, and Huons has not yet established the candidate's safety or efficacy in patients.
Huons plans to initially develop HUC1-622 for rare forms of obesity while exploring its potential application in broader obesity treatment. Further studies will assess dose-dependent efficacy and its potential use in combination with GLP-1 receptor agonists or as maintenance therapy.
"HUC1-622 is a drug candidate designed from the outset to address the core challenges of MC4R agonists, which are AgRP resistance, sustained signaling, and receptor selectivity," said Kyung-mi Park, vice president and head of research and development at Huons.
"We will continue to systematically validate its efficacy and safety in subsequent studies," Park added.





